EndoArt Artificial Endothelial Layer for Chronic Corneal Edema
- Specialists at the European Society of Cataract and Refractive Surgeons winter meeting have presented multiple studies showing positive results for the EndoArt artificial endothelial layer.
- Developed by EyeYon Medical, based in Ness Ziona, Israel, EndoArt serves as a synthetic alternative to human corneal transplants.
- Ruth Lapid, MD, PhD, described the device by stating, It looks like a contact lens, only you put it inside the eye and not on top of the...
Specialists at the European Society of Cataract and Refractive Surgeons winter meeting have presented multiple studies showing positive results for the EndoArt artificial endothelial layer. The device is designed to treat chronic corneal edema, specifically in complex cases where conventional endothelial keratoplasty has failed.
Developed by EyeYon Medical, based in Ness Ziona, Israel, EndoArt serves as a synthetic alternative to human corneal transplants. The device adheres to the posterior surface of the cornea, where it acts as a barrier to the transfer of fluids.
Ruth Lapid, MD, PhD, described the device by stating, It looks like a contact lens, only you put it inside the eye and not on top of the cornea.
Material Composition and Design
The EndoArt implant is constructed from a biocompatible acrylic hydrophilic material. Specifically, it is made of a copolymer consisting of hydroxyethyl methacrylate and methyl methacrylate.
The device features a dome-shaped profile tailored to match the posterior surface of the cornea. Its physical specifications include a diameter of 6.50 mm and a thickness of 50 μm.
Clinical Application and Outcomes
The primary objective of the device is the management of chronic corneal edema. Clinical research has focused on examining the outcomes and morphological corneal changes that occur following the implantation of the artificial layer.
According to reports published on October 1, 2025, EndoArt may provide a therapeutic option for patients with complex corneal edema who have not seen success with conventional endothelial keratoplasty.
Regulatory Status and U.S. Clinical Studies
The U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) approval to EyeYon Medical on December 8, 2025. This approval allows the company to initiate a clinical study in the United States to evaluate the first artificial endothelial layer for the treatment of corneal edema.
The initiation of these U.S. Trials follows the reporting of the device’s efficacy in managing chronic corneal edema in earlier studies.